Skip to content

A controlled clinical trial investigating the impact of point of care testing for ‘atypical’ pneumonia, bordetella pertussis and viral pathogens on patient pathways, antimicrobial consumption and cost-efficiency.

Point of care testing for respiratory pathogens

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10470967
Enrollment
2262
Registered
2015-11-06
Start date
2015-01-05
Completion date
Unknown
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rapid PCR-based diagnostic test when placed at the point of care Infections and Infestations

Interventions

1. Control: combined nose and throat swabs for respiratory virus testing with the laboratory -based PCR testing +/- atypical investigations e.g. serology 2. Intervention: combined nose and throat swab

Sponsors

King's College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. = 16 years of age 2. Have mental capacity to give written informed consent to participate in the study 3. Have acute upper respiratory tract infection or influenza-like illness +/- lower respiratory tract infection. Symptoms include fever or feeling feverish (chills), cough, sore throat, runny or stuffy nose, muscle-aches or body-aches, headaches, fatigue (tiredness), some people may have vomiting or diarrhoea (though this is more common in children than adults). Please note that not all patients with influenza have fever. Please note that patients with a clinical or radiological diagnosis of community-acquired lower respiratory tract infection, evidence/suspicion of bacterial infection with common, ‘typical’ respiratory tract pathogens, patients with known or suspected immune suppression, and those with sepsis or severe sepsis are also eligible for inclusion.

Exclusion criteria

Exclusion criteria: 1. Those who do NOT meet the inclusion criteria 2. Evidence/suspicion of bacterial infection affecting sites other than the respiratory tract

Design outcomes

Primary

MeasureTime frame
Antibiotic use and length of hospital stay

Secondary

MeasureTime frame
1. Turnaround time of tests 2. Readmission rate 3. Mortality 4. Ease of use of Point of Care Test 5. Cost benefit

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 26, 2026